Invest in intelligence that delivers

Spherix Market Expertise

Our team of experts and physician
community give you a competitive edge.

See the market from the prescribers’ point of view.

Our physician community includes direct relationships with our curated physician network and leading KOLs, who keep us closely connected with the specific challenges of specialty markets.

Vetted Practicing Physicians

Key Opinion Leaders

Professional Organizations

3,300+ members in the Spherix US Physician Community

Our therapeutic experts are always just a click or call away...

  • Plugged into the ever-evolving landscape
  • Ready to provide an unbiased view of the landscape
  • Insightfully answer real-time questions
  • Highlight opportunities 
  • Identify disruptors

Dermatology

Expertise

7

dedicated team members

10

years of
continuous tracking

56

studies published annually

Indications

  • Alopecia Areata (AA)
  • Asthma
  • Atopic Dermatitis (AD)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Spontaneous Urticaria (CSU)
  • Hidradenitis Suppurativa (HS)
  • Plaque Psoriasis (PsO)
  • Prurigo Nodularis (PN)
  • Vitiligo

Team Lead

Andy Stankus
Franchise Head, Dermatology

Andy, with a pharmaceutical marketing MBA, has 27+ years of experience in life sciences and healthcare consultancy creating commercial strategy, differentiation and real-world value.  Prior to Spherix, Andy led global product launches at Johnson & Johnson, data and research consulting teams at Kantar Health / Oracle Life Sciences, and enjoys publishing and speaking across multiple therapeutic areas at international conferences.  In addition to this broad therapeutic expertise, given a specific passion in dermatology, Andy and teams he has led have been lead authors on more than 145 dermatology publications across 20+ life sciences organizations.

Gastroenterology

Expertise

6

dedicated team members

10

years of
continuous tracking

54

studies published annually

Indications

  • Celiac Disease
  • Crohn’s Disease 
  • Eosinophilic Esophagitis (EoE)
  • Irritable Bowel Syndrome (IBS)
  • Metabolic dysfunction–associated steatotic liver disease / steatohepatitis (MASLD / MASH) (previously NAFLD/NASH)
  • Obesity
  • Primary Biliary Cholangitis (PBC)
  • Primary Sclerosing Cholangitis (PSC)
  • Ulcerative Colitis

Team Lead

Jim Hickey
Franchise Head, Gastroenterology

Jim has 20+ years’ experience building and leading research teams, pioneering innovative research techniques, and providing insight solutions to pharmaceutical brands. Prior to Spherix, he led the research team at Verilogue from early startup through its acquisition by Publicis Health. Jim has extensive experience across a wide range of therapeutic categories and a particular interest in gastroenterology and inflammatory disease.

Rheumatology

Expertise

6

dedicated team members

10

years of
continuous tracking

37

studies published annually

Indications

  • Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (AS and nr-AxSpA)
  • Cell Therapy
  • Connective Tissue Disease–Interstitial Lung Disease (CTD-ILD)
  • Cutaneous Lupus (CLE)
  • Dermatomyositis (DM)
  • Giant Cell Arteritis (GCA)
  • Idiopathic Inflammatory Myopathy (IIM)
  • Lupus Nephritis (LN)
  • Polymyalgia Rheumatica (PMR)
  • Psoriatic Arthritis (PsA)
  • Rheumatoid Arthritis (RA)
  • Sjögren’s Syndrome (SjS)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)

Team Lead

Lynn Price
Franchise Head, Rheumatology

Lynn has over eight years at Spherix, leading
strategic initiatives and insights development.
She previously, directed research analytics at
Decision Resources Group and managed
immunology research at BioTrends, with
extensive experience in data analysis and
client relations in the biopharmaceutical
sector.

Nephrology

Expertise

7

dedicated team members

10

years of
continuous tracking

43

studies published annually

Indications

  • APOL-mediated Kidney Disease
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Chronic Kidney Disease, Non-Dialysis (CKD-ND)
  • Complement Disorders
  • Complement 3 Glomerulopathy (C3G)
  • Dialysis
  • Fabry’s Disease (FD)
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Hyperkalemia (HK)
  • Hyperphosphatemia (HPhos)
  • Hypertension in Chronic Kidney Disease (HTN in CKD)
  • IgA Nephropathy (IgAN)
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
  • Lupus Nephritis (LN)
  • Membranous Nephropathy (MN)
  • Renal Anemia

Team Lead

Kari McCarthy
Franchise Head, Nephrology

Kari has more than 20 years of experience in healthcare, strategy and insights, with a strong track record in brand development, market research, and strategic narrative building. Most recently, Kari was the VP of Strategy at DDB Health, where she led brand strategy for nephrology and oncology brands. 

Neurology

Expertise

7

dedicated team members

10

years of
continuous tracking

35

studies published annually

Indications

  • Alzheimer’s Disease (AD)
  • Bipolar Disorder (BD)
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Epilepsy
  • Generalized Myasthenia Gravis (gMG)
  • Huntington’s Disease (HD)
  • Major Depressive Disorder (MDD)
  • Migraine
  • Multiple Sclerosis (MS)
  • Parkinson’s Disease (PD)
  • Schizophrenia (SCZ)

Team Lead

Bob Shewbrooks

Franchise Head, Neurology

Bob has over 25 years of industry experience, having held roles at Wyeth (Pfizer), Otsuka, and Sumitomo, supporting business units and brands. He brings significant experience on the supplier side in consulting, as well as primary and syndicated market research, driving growth and innovation across portfolios.

Ophthalmology

Expertise

8

dedicated team members

3

years of
continuous tracking

19

studies published annually

Indications

  • Age-Related Macular Degeneration (AMD)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Dry Eye Syndrome (DES)
  • Geographic Atrophy (GA)
  • Gene Therapies in Retinal Disorders
  • Glaucoma
  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Thyroid Eye Disease (TED)
  • Uveitis

Team Lead

Bob Shewbrooks

Franchise Head, Ophthalmology

Bob has over 25 years of industry experience, having held roles at Wyeth (Pfizer), Otsuka, and Sumitomo, supporting business units and brands. He brings significant experience on the supplier side in consulting, as well as primary and syndicated market research, driving growth and innovation across portfolios.

Hematology/Oncology

3

dedicated team members

9

years of
continuous tracking

34

studies published annually

Indications

  • Autoimmune Hemolytic Anemia (w-AIHA)
  • Hemophilia A & B
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Sickle Cell Disease (SCD)
  • Immune Thrombocytopenic Purpura (ITP)
  • Thalassemia
  • Chronic Lymphocytic Leukemia (CLL)
  • Large B-Cell Lymphoma (LBCL)
  • Multiple Myeloma (MM)
  • Myelodysplastic Syndrome (MDS)
  • Von Willebrand Disease (vWD)

Team Lead

Sarah Hendry

Franchise Head, Hematology/Oncology

Sarah has over a decade of experience managing custom and syndicated projects, specializing in hematology/oncology.  She brings deep expertise in brand strategy and patient-centered communications within healthcare and pharma. Most recently, Sarah led brand strategy execution for CAR-T therapies at DDB Health, working closely with pharmaceutical partners to enhance engagement and brand growth. In her previous research roles at Verilogue and Maslansky + Partners, she worked extensively in hematology, including co-authoring an article in the Orphanet Journal of Rare Diseases on the lexicon for gene therapy in hemophilia B, communicating the complement cascade in PNH, and analyzing market dynamics in myeloma and B-cell malignancies.

Sign up for alerts, market insights and exclusive content in your inbox.